Brief: Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
13/10/2026 05:10
BRIEF-Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA Oct 13 (Reuters) - Formycon AG FYB.DE:
EQS-NEWS: FORMYCON AND ZYDUS: FYB206 BECOMES FIRST PUBLICLY ANNOUNCED KEYTRUDA® BIOSIMILAR ACCEPTED FOR REVIEW BY FDA
Source text: ID:nEQ6xS6mVa
Further company coverage: FYB.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Formycon AG
See all newsBrief: Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication
Brief: FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
Brief: Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
Brief: Formycon AG - Clinical Development Of FYB206 Completed In July 2026
Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows